Ra Medical Systems Inc (RMED) Quote

$VTAK Catheter Precision, Inc. (NYSE American:VTAK) Announces the First use of VIVO in Qatar

https://www.accesswire.com/842864/catheter-precision-inc-nyse-american-vtak-announces-the-first-use-of-vivo-in-qatar

FORT MILL, SC / ACCESSWIRE / March 14, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based medical device company focused on innovative electrophysiology products, announced that VIVO was used in five procedures for the first time in Qatar at Hamad Medical Corporation Heart Hospital in Doha. Hamad Medical Corporation (HMC) is the main provider of secondary and tertiary healthcare in Qatar and one of the leading hospital providers in the Middle East. HMC manages 12 hospitals - nine specialist hospitals and three community hospitals.

"VIVO was recently used for five patients at Doha Heart Hospital in Qatar.", said David Jenkins, CEO of Catheter Precision. He continued, "The physicians were impressed with the accuracy of VIVO and we look forward to expanding our footprint in the middle east and continuing to show the benefits of VIVO in new territories."

$VTAK Catheter Precision, Inc. (NYSE American: VTAK) Announces the First use of LockeT Outside of the United States

https://www.accesswire.com/841419/catheter-precision-inc-nyse-american-vtak-announces-the-first-use-of-locket-outside-of-the-united-states

FORT MILL, SC / ACCESSWIRE / March 11, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based medical device company focused on electrophysiology products, announced that LockeT was used for the first time outside of the United States at Hamad Medical Corporation Heart Hospital in Doha, Qatar. Hamad Medical Corporation (HMC) is the main provider of secondary and tertiary healthcare in Qatar and one of the leading hospital providers in the Middle East. HMC manages 12 hospitals - nine specialist hospitals and three community hospitals.

After using LockeT, Dr. Sajad Hayat said, "A vascular hemostasis [product] should be simple to use and effective. The LockeT venous hemostasis device combines the simplicity of a figure of 8 suture but with a more controlled delivery and release making it ideal. Importantly, it simplifies post procedure care facilitating early mobilization and discharge."

"Not only were the first cases outside of the United States successful, but the value of the product was immediately observed by the physician," said David Jenkins, CEO of Catheter Precision, Inc. "Dr. Hayat was quick to observe that LockeT is not only simple in design, but simple to use and that it effectively creates hemostasis and provides additional benefits to the patient and hospital staff."

$VTAK Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now


https://www.globenewswire.com/news-release/2024/03/06/2841245/0/en/Presenting-on-the-Emerging-Growth-Conference-68-Day-2-on-March-7-Register-Now.html

2:55 - 3:05
Catheter Precision, Inc. (NYSE American: VTAK)
Keynote speaker: David Jenkins, Executive Chairman & Interim CEO

Catheter Precision Inc (NYSE American: VTAK) Marks Milestone: VIVO Used Successfully with Pediatric Patient


https://www.marketscreener.com/quote/stock/CATHETER-PRECISION-INC-46372038/news/Catheter-Precision-Inc-NYSE-American-VTAK-Marks-Milestone-VIVO-Used-Successfully-with-Pediatric-46072077/

The medical equipment sector is presently highly coveted by investors, and if you're exploring companies in this field, consider investigating Catheter Precision Inc. (NYSE American: VTAK). This U.S.-based medical device firm specializes in electrophysiology products and recently unveiled a significant announcement.

On Wednesday, February 28, 2024, Catheter Precision, Inc. (NYSE American: VTAK) experienced an 8.69% increase, closing higher than usual trading volumes. This marks the third consecutive day of gains, forming a Bullish Swing Set-up alongside other positive indicators. Furthermore, the stock is currently trading above its 10, 20, and 50-day moving averages. With VTAK's 52-week high at $2.80, breaking its 200-day moving average of $0.60 could potentially propel the stock to even greater heights.

The corporation disclosed that its product, VIVO, was utilized for the inaugural time on a pediatric patient in Turkey. This revelation surfaced shortly after Catheter Precision declared a fresh distribution collaboration with Ege Artimi, a company operating in the Turkish market, just last month.

David Jenkins, the CEO, commented on this advancement, emphasizing that VIVO stands out as a premier device designed for pre-procedure planning in pediatric cases. This non-invasive tool is particularly useful before ventricular ablations, offering tailored patient-specific information to physicians without additional risk. Jenkins highlighted that deploying VIVO in sensitive patients showcases its adaptability and diverse advantages.

The corporation primarily focuses on pioneering technology for electrophysiology procedures, achieved through impactful partnerships with physicians, which foster ongoing enhancements in its offerings. Initially established as Ra Medical in Delaware in 2018, the company rebranded as Catheter Precision Inc. on August 17, 2023. VIVO stands out as one of its key products, having already garnered substantial traction across various markets. The company aims to expand the product's reach into additional markets.

$VTAK Catheter Precision, Inc. (NYS American:VTAK) Announces Attendance at the International Symposium on Left Atrial Appendage

https://www.accesswire.com/836529/catheter-precision-inc-nys-american-vtak-announces-attendance-at-the-international-symposium-on-left-atrial-appendage

FORT MILL, SC / ACCESSWIRE / February 26, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based medical device company focused on novel electrophysiology products, announced that the Company is showcasing their LockeT suture closure device at the International Symposium on Left Atrial Appendage. The annual ISLAA conference is taking place at the Intercontinental New York Times Square in New York City from March 1 - 2, 2024.

Catheter Precision's CEO, David Jenkins, said, "Last week VTAK announced that the initial clinical data on LockeT was shared at the Western Atrial Fibrillation Symposium with great response from physicians and industry. Last week's meeting focused on advancements in Atrial Fibrillation, but this ISLAA will focus on the Left Atrial Appendage (LAA) and expands the audience to all cardiovascular physicians. LockeT's use in LAA procedures enables the benefits of our closure device to go beyond electrophysiology procedures."

The ISLAA conference is an internationally recognized meeting focused on educating physicians, nurses and allied health professionals in the fields of electrophysiology, cardiology, family and internal medicine about the Left Atrial Appendage (LAA). Educational sessions are led by world-renowned faculty and the symposium will offer very informative presentations on the anatomy, physiology and pathological aspect of the LAA, along with old and new therapeutic strategies of stroke prophylaxis including cardiac devices for LAA exclusion.

$VTAK Catheter Precision, Inc. Announces the Presentation of the First Clinical Data on LockeT


https://www.accesswire.com/835665/catheter-precision-inc-announces-the-presentation-of-the-first-clinical-data-on-locket

FORT MILL, SC / ACCESSWIRE / February 22, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US-based medical device company focused on novel electrophysiology products, announced that the clinical data from the first LockeT study will be presented at the Western Atrial Fibrillation Symposium (Western AFib). The 17th annual Western AFib conference is taking place in Park City, Utah from February 23 - 24, 2024.

Catheter Precision's CEO, David Jenkins, said, "We are very excited to have the initial LockeT clinical data available to share with physicians. This study demonstrates that LockeT is not only safe and effective in achieving hemostasis but that it provides additional benefits of cost savings and same-day hospital discharge."

The Western Afib symposium is an internationally recognized meeting focused on improving outcomes worldwide and features experts from the atrial fibrillation community. Educational sessions are led by world-renowned faculty and include topics related to advancements in diagnosing and treating atrial fibrillation and focused roundtable discussions.

$VTAK Catheter Precision, Inc. Participates in AF Symposium

https://www.accesswire.com/828798/catheter-precision-inc-participates-in-af-symposium

FORT MILL, SC / ACCESSWIRE / January 29, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products is participating in the AF Symposium conference. The AF Symposium is taking place in Boston, Massachusetts from February 1-3, at the Omni Seaport Hotel. The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation. Over the past 29 years, the meeting has become a major scientific forum at which healthcare professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent investigators in the field. The Electrophysiology product divisions from other large companies will be attending including Medtronic (MDT), Boston Scientific (BSX), Abbott (ABT), and Johnson and Johnson (JNJ).

David Jenkins,CEO of Catheter Precision, said, "Participation in medical device conferences enables us to showcase our products to a dedicated audience of physicians. A conference like AF Symposium is unique in that it is dedicated to electrophysiologists. So, while it may be a smaller gathering it is also a very targeted audience and enables us to show our VIVO mapping system and LockeT suture retention device and generate leads and create additional interest."

$VTAK Catheter Precision, Inc. (VTAK) Secures New Distributor for VIVO in Turkey

https://www.accesswire.com/827949/catheter-precision-inc-vtak-secures-new-distributor-for-vivo-in-turkey

FORT MILL, SC / ACCESSWIRE / January 25, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced that it has signed a new distributor for Turkey for VIVO, a non-invasive 3D localization system. Ege Artimi, located in Izmir, Turkiye (Turkey), was founded in 2014 and specializes in importing and providing clinical support to cardiology products.

European Sales Manager, Fatih Ayoglu, said, "A few months ago we successfully began using VIVO in Croatia. Adding a distributor in Turkey is another step towards expanding our footprint in Eastern Europe. We are excited to bring our VIVO technology to other countries and to give physicians a cost-effective solution for pre-procedure planning."

"Catheter Precision is continuously searching for and adding distribution partners", said David Jenkins, interim CEO. "Finding distribution partners enables us to expand our sales territory without the need for a direct sales force. It also allows us to utilize personnel that are familiar with the local regulations to help navigate local approval processes which is the first step to expanding the VIVO market."

$VTAK Catheter Precision, Inc. (VTAK) Secures New Distributor in Brazil for LockeT

https://www.accesswire.com/826816/catheter-precision-inc-vtak-secures-new-distributor-in-brazil-for-locket

FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced that it has completed a distribution agreement with Supri Artigos Medico Artigos Hospitalares Ltda ("SUPRI") for LockeT in Brazil. Supri, located in Sao Palo, Brazil, is an importer and distributor of medical and hospital articles and equipment and was founded 2005 and specializes in the cardiology and electrophysiology field.

David Jenkins, interim CEO, says, "This is our first distributor in South America for LockeT. It is always exciting to expand into new territories and provide physicians and patients with novel technologies that enable them to streamline their workflows and improve patient care while remaining cost effective."

$VTAK Catheter Precision’s VIVO System Featured in Electrophysiology Publication

https://www.accesswire.com/825550/catheter-precisions-vivo-system-featured-in-electrophysiology-publication

FORT MILL, SC / ACCESSWIRE / January 17, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a leader in non-invasive 3D mapping for ventricular arrhythmias, announced that their VIVO System was highlighted as part of a case study in the current issue of EP Lab Digest. EP Lab Digest is an educational, monthly publication dedicated to electrophysiology with both print and online content.

"Physicians often present case studies to publications for new and innovative products." Said David Jenkins, CEO of Catheter Precision. "Having a case study selected means that the publication committee believes the work presented by the physicians at NYU is valuable for other electrophysiologists. This case study is unique in that it falls under a physician-initiated study and combines two different mappin

$VTAK CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results

https://www.accesswire.com/823629/catheter-precision-inc-vtak-reports-unaudited-preliminary-fourth-quarter-and-full-year-2023-results

FORT MILL, SC / ACCESSWIRE / January 10, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights and unaudited preliminary annual and fourth quarter results of 2023.

Unaudited preliminary results of the fourth quarter and year ended December 31, 2023, include the following:

Total revenues for the quarter and year ended December 31, 2023, were approximately $129,000 and $442,000, respectively.
Total cash on hand as of December 31, 2023, was approximately $3.6 million.
Total assets as of December 31, 2023, subject to adjustment, was $30.7 million.
Shareholders equity as of December 31, 2023, subject to adjustment was $19.4 million.
Preliminary net loss, subject to adjustment for the quarter and year ended December 31, 2023, was approximately ($2.5) million and ($72.4) million, respectively. A one-time $61 million write off for impairment of goodwill is reflected in the net loss for the year ended December 31, 2023.
Highlights of the year ended December 31, 2023, include the following:

Onboarded and trained sales and clinical personnel in the US.
Launched LockeT closure product in the US.
Completed enrollment of Phase I LockeT study including more than 100 patients with a completed and submitted manuscript.
Received Institutional Review Board (IRB) approval for Phase II LockeT study and began enrolling patients. This study is a one-to-one randomized study comparing outcomes of standard of care to LockeT.
Finalized new build processes for VIVO disposable component to reduce manufacturing costs.
Received approval for first VIVO purchase in France. VIVO is now active in six European countries.
Continued expansion of our intellectual property (IP), now having 50 patents worldwide.
David Jenkins, CEO, commented: "We have a lot of momentum as we move into 2024. Our sales and clinical team have successfully introduced VIVO and LockeT to new hospital centers and the products have been well received. Over the next several months we expect hospital approval to begin additional product evaluations and subsequent purchase orders. Catheter Precision's VIVO System continues to support the electrophysiologist and hospital in growing their ventricular ablation programs, which we believe will rival the atrial fibrillation market in the future. LockeT offers a more affordable and easier to use option for wound closure and the first manuscript demonstrating these benefits has been submitted for publication and should be available soon."

These preliminary results are based on management's initial analysis of operations for the quarter and year ended December 31, 2023, and are subject to completion of the Company's year-end financial reporting processes, further internal review, potential adjustments and audit by the Company's external auditors. Items to further consider in the completion of the results include the analysis of impairment to intangible assets and liabilities pertaining to potential royalties payable in the future, which could materially impact our final results.

$VTAK Catheter Precision, Inc. (VTAK) Announces Changes to Executive Management and Board of Directors

https://www.accesswire.com/821464/catheter-precision-inc-vtak-announces-changes-to-executive-management-and-board-of-directors

FORT MILL, SC / ACCESSWIRE / January 3, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, today announced changes to the executive management and board of directors, including a change to the Chief Financial Officer. Mr. Passey's employment was terminated effective December 31, 2023. In his place, the Board of Directors has appointed Margrit Thomassen, CPA, to be interim Chief Financial Officer as of January 2, 2024. Margrit has been a full-time employee at the Company's Catheter Precision subsidiary since 2019 and has served as controller of the Company since the acquisition of Catheter Precision by Ra Medical in January 2023.

In addition, David Jenkins, previously Interim Chief Executive Officer, is named Chief Executive Officer effective January 2, 2024. He will continue as Executive Chairman of the Board. Susanne Meline has resigned from the Board of Directors as of December 28, 2023, and is replaced by John Francis as of January 2, 2024. Mr. Francis, Ms. Meline's spouse, is a Managing Member of Francis Capital Management, LLC, an investment management firm specializing in small capitalization equities, since 2000. He has more than 20 years of experience in investment management, finance, accounting and has extensive experience investing in small cap medical device companies.

David Jenkins, CEO, said. "We look forward to starting the new year with Margrit as interim CFO as well as adding John Francis to the Board of Directors. Margrit has been an integral part of Catheter Precision as Controller for many years now and it was a logical step to ask her to become interim CFO. John's previous experience is an asset to Catheter Precision as we continue to grow our business and strive to meet the needs of patients, hospitals, and physicians."

$VTAK Catheter Precision, Inc. (VTAK) Receives Additional Patents for LockeT in Great Britain and the European Market

https://www.accesswire.com/821195/catheter-precision-inc-vtak-receives-additional-patents-for-locket-in-great-britain-and-the-european-market

New Patents Demonstrate Uniqueness of the Closure Product Design

FORT MILL, SC / ACCESSWIRE / January 2, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products, announced today that Great Britain and the European Market have allowed two new patents (No. 6288592 and No. 015023977-0001), further strengthening the company's IP position for its LockeT product line. These new issued patents for LockeT are in addition to an issued patent in Japan earlier in 2023.

David Jenkins, interim CEO, said, "The new issued patents and patent applications in Great Britain and the European Market now brings the total number to 50. The new patents demonstrate Catheter Precision's commitment to developing and maintaining the uniqueness of the closure product design, which is currently available in the United States and under review for CE mark. We are pleased with the new and continued development of LockeT and look forward to continuing to add to our LockeT IP."

$VTAK Catheter Precision, Inc. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q

https://www.accesswire.com/819336/catheter-precision-inc-reports-third-quarter-results-of-operations-and-filing-of-third-quarter-10-q

FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023.

Highlights of the third quarter include the following:

Received approval for first purchase in France. VIVO is now active in six European countries.
Completed enrollment of Phase I LockeT study in excess of 100 patients.
Received Institutional Review Board (IRB) approval for Phase II LockeT study and began enrolling patients. This study is a one-to-one randomized study comparing outcomes of standard of care to LockeT.
Finalized new build processes for VIVO disposable component to reduce manufacturing costs.
Initiated design changes to LockeT based on early feedback.
Total assets at September 30, 2023, were $32.9 million.
Total cash on hand at September 30, 2023 was $5.6 million.
Total revenues for the nine months ended September 30, 2023 were $314 thousand.
David Jenkins, acting CEO, commented: "We are pleased to have the Q3 financial filings completed and have a lot of momentum as we move into the fourth quarter. Our sales and clinical team have successfully introduced VIVO and LockeT to a number of new hospital centers and the products have been well received. Over the next several months we expect hospital approval to begin additional product evaluations and subsequent purchase orders. Catheter Precision's VIVO System continues to support the electrophysiologist and hospital in growing their ventricular ablation programs, which we believe will rival the atrial fibrillation market in the future. LockeT offers a more affordable and easier to use option for wound closure and the first publication demonstrating these benefits is underway and will be available soon."

$VTAK CATHETER PRECISION, INC. Reports Filing of 10-Q and Second Quarter Results of Operations

https://www.accesswire.com/817842/catheter-precision-inc-reports-filing-of-10-q-and-second-quarter-results-of-operations

FORT MILL, SC / ACCESSWIRE / December 18, 2023 / Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (NYSE American:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023.

Highlights of the second quarter include the following:

US sales team was assembled, trained, and is creating a pipeline.
Additional US clinical personnel were onboarded and trained.
Completion of enrollment of 125 patient VIVO patient Registry. Follow-up data is expected to be completed in June 2024.
Key VIVO accounts continue to be established in both the US and Europe.
Initiation of first LockeT study, to include 100 patients, to demonstrate time to hemostasis, time to patient ambulation, and time to hospital discharge. This observational study is intended to clinically show a new cost-effective alternative to existing closure methods.
Onboarded a consulting group to bring about international contracts for the distribution of the LockeT closure product.
Continued pursuit of intellectual property filings for both VIVO and LockeT technologies.
Total assets at June 30, 2023, were $35.5 million.
Total cash on hand at June 30, 2023 was $7.4 million.
Total revenues for the six months ended June 30, 2023, were $181,000.
Completed the accounting for the merger transaction between Ra Medical Systems and Catheter Precision, including the valuation of the consideration exchanged and the allocation of the purchase price to the different assets and liabilities on the balance sheet, including the various intangible categories.
David Jenkins, acting CEO, commented: "We are pleased to put the accounting related to the merger behind us, and we now look forward to moving forward as a public company. Our VIVO and LockeT products are now in the introductory stage in the U.S. market, and we are quite satisfied with the initial response. Early commercial feedback has set the stage for greater success over the coming years."

Mr. Jenkins continued, "We continue to believe that our unique technologies are favorably positioned within the cardiac electrophysiology market. Our VIVO product, an acronym for "View into Ventricular Onset," is a unique non-invasive mapping system to show early activation in ventricular arrhythmias. We believe that ablation for ventricular arrhythmias has the potential for huge growth, to mirror that of the atrial fibrillation ablation market. VIVO is a tool that, when used in the clinical setting, allows for an accurate visualization and shorter procedure times. LockeT, a suture retention device utilized after percutaneous venous access, is easy to use and comfortable for the patient. Early clinical use has demonstrated short times to achieve hemostasis and to ambulation at a lower cost to the hospital than other closure devices. The first study data, to include 125 patients, is expected to be available soon."

$VTAK Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Emerging Growth Conference on December 6, 2023

https://www.accesswire.com/813088/catheter-precision-inc-nyse-americanvtak-presenting-at-the-emerging-growth-conference-on-december-6-2023

FORT MILL, SC / ACCESSWIRE / December 5, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) is pleased to announce that it has been invited to present at the Emerging Growth Conference on December 6, 2023. Catheter Precision, Inc. (NYSE American: VTAK) will be discussing VIVO™, its innovative non-invasive, 3D mapping system that enables physicians to identify the origin of ventricular cardiac arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO received marketing clearance from the U.S. FDA and is commercially available in Europe. VIVO is designed to provide an innovative cost-effective solution for improving the treatment of cardiac arrhythmias among other company topics.

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chief Executive Officer in real time. Individual and institutional investors, as well as advisors and analysts, are invited to attend its real-time, interactive presentation at the Emerging Growth Conference.

David Jenkins, CEO will give a presentation and may subsequently open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and he will do his best to get through as many of them as possible.

Catheter Precision, Inc. (NYSE American:VTAK) will be presenting at 11:25am Eastern time for 30 minutes.

Please register here to ensure you can attend the conference and receive any updates that are released.

https://emerginggrowth.com/emerging-growth-conference-65/

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.

$VTAK Catheter Precision's (VTAK) First Successful VIVO(TM) Cases Completed in Croatia Sets Stage for Expansion into South-Eastern Europe


https://www.accesswire.com/806245/catheter-precisions-vtak-first-successful-vivotm-cases-completed-in-croatia-sets-stage-for-expansion-into-south-eastern-europe

FORT MILL, SC / ACCESSWIRE / November 20, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a pioneering medical technology firm headquartered in the United States, specializing in electrophysiology devices, has proudly disclosed the successful conclusion of the inaugural VIVO cases in the region of South-Eastern Europe. VIVO, the Company's innovative 3D non-invasive imaging system, is used pre-procedurally to identify areas of interest for ventricular ablation and aid in pre-procedure planning to reduce procedure time and aid in procedural accuracy.

VIVO was assessed during four ventricular ablation procedures at Dubrava University Hospital in Zagreb, Croatia. Dr. Ivan Zeljkovic, Head of Electrophysiology Lab at Dubrava University Hospital stated, "The VIVO workflow is simple and flexible, and I was impressed with the accuracy of the VIVO maps which certainly exceeded my expectations! Having the VIVO maps pre-procedurally, allowed us to accurately target the anatomic location of the ventricular arrhythmia and has the potential to increase procedural efficacy."

"This is the first step to expanding VIVO's presence in South-Eastern Europe" stated Patricia Kennedy, Chief Commercialization Officer. "The evaluation yielded positive results, and we anticipate a purchase order soon. Dr. Zeljkovic reiterated what we have always known to be true about VIVO: it is accurate, easy to use, and non-invasive localization provided to the physician pre-procedurally has the potential to improve procedural outcomes."

$VTAK Catheter Precision's VIVO is Now Eligible for National Reimbursement in the UK

https://www.accesswire.com/792220/catheter-precisions-vivo-is-now-eligible-for-national-reimbursement-in-the-uk

The National Health System England Grants VIVO™ Additional Reimbursement

FORT MILL, SC / ACCESSWIRE / October 12, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announces that its VIVO 3D mapping system has been granted national reimbursement in the UK after inclusion in the High-Coast Tariff Excluded Devices (HCTED). VIVO enables physicians to identify the origin of ventricular arrhythmias pre-procedure, streamlining workflow and reducing procedure time.

Dr. Moloy Das consultant Cardiologist & Electrophysiologist at the Freeman Hospital located in Newcastle, UK says, "I am delighted that VIVO is now available via the HCTED/Specialized Services Devices program. This will allow greater access to this technology for patients who would benefit from its use in their procedure."

HCTED is a nationwide purchase and supply system for the National Health Service England (NHS England) designed to pay for products that qualify for separate payment from the national budget for medical procedures. Hospitals are now able to bill the cost of the of the single use component directly to the NHS.

Patricia Kennedy, Chief Commercial Officer said, "Over the last couple of years we have created a footprint with several hospitals utilizing our VIVO technology. Now that VIVO has been accepted to HCTED, we believe this will further support the adoption of the VIVO technology and allow for greater market access and expanded reimbursement."

$VTAK Catheter Precision Showcasing its Innovative 3D Mapping System

https://www.accesswire.com/791410/catheter-precision-showcasing-its-innovative-3d-mapping-system

VIVO to Be Highlighted at Several Electrophysiology Conferences

FORT MILL, SC / ACCESSWIRE / October 10, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK) announced that its innovative 3D Mapping system will be highlighted at several electrophysiology conferences this fall.

Most recently, VIVO was highlighted at the 19th Congresso Nazionale Associazione Italiana di Aritmologia e Cardiostimolazione in Bologna, Italy from September 21-22. Interim CEO David Jenkins remarked, "Our attendance not only highlighted our state-of-the-art technology but also cemented collaborations for evaluations at prominent VIVO sites, including Ospedale Della Misericordia Grosseto and Pisa CNR. VIVO received commendable feedback, recognizing its potential to revolutionize patient experience and EP lab efficiency."

Strengthening their foothold in Italy, Catheter Precision has strategically partnered with Precise S.r.l. "Our alliance with Precise S.r.l. is instrumental in solidifying our presence in the Italian medical landscape," Jenkins concluded.

In addition to VIVO, Catheter Precision will be present at other conferences also highlighting their newly introduced product, LockeT, a venous stasis closure device.

Future conferences that will highlight VIVO in the coming weeks are listed below.

Irish Cardiac Society's 74th Annual Scietific Meeting, October 12-14, 2023:
Presentation: "Testing the Validity of VIVO Technology: A Deep Dive into Ventricular Onset Mapping" by Professor Szeplaki's team from Mater Private Hospital, Dublin.
18th Annual International Symposium on Ventricular Arrythmias, October 13-14, 2023
Location: Philadelphia, Pennsylvania
Spotlight: VIVO and LockeT products
7th Annual Society of Cardiac RN Meeting, October 19-20, 2023:
Location: Washington, DC
Presentation: "3D Mapping for Robotic Ventricular Ablations Using VIVO" by Dr. Benjamin D'Souza from Penn Presbyterian Medical Center, Philadelphia, PA.

$VTAK Catheter Precision, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

https://www.accesswire.com/781401/catheter-precision-inc-to-participate-in-the-hc-wainwright-25th-annual-global-investment-conference

Management Presentation on September 11, 2023 at 7:00 am ET

FORT MILL, SC / ACCESSWIRE / September 7, 2023 / Catheter Precision, Inc. (NYSE American:VTAK) announced today that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11 - 13th.

David Jenkins, interim CEO, is scheduled to virtually present on September 11, 2023, starting at 7:00 am ET. Interested parties are invited to register at https://hcwevents.com/annualconference. The event is also being held virtually for those who cannot attend in person.

$VTAK Catheter Precision Secures New Distribution Partner for Southeast Asia

https://www.accesswire.com/778879/catheter-precision-secures-new-distribution-partner-for-southeast-asia

FORT MILL, SC / ACCESSWIRE / August 31, 2023 / Catheter Precision, Inc. (the"Company") (NYSE American:VTAK) announced that the Company entered a distribution partnership with Somnotec (S) Pte Ltd., a medical device distributor based in Singapore. Somnotec will distribute the LockeT closure device in Singapore, Philippines, Malaysia, Indonesia and Brunei.

"LockeT is CPI's newest product line, and we are eager to expand the footprint beyond the United States. Partnering with a large company like Somnotec is the first step in achieving this goal," said David Jenkins, Interim CEO. "We are continuing to identify potential partnerships for LockeT to expand into new territories to include South America, Central America, the Middle East, Japan and Australia."

$RMED Reminder: Ra Medical Systems Announces Name and Ticker Symbol Changes

https://www.accesswire.com/774776/Reminder-Ra-Medical-Systems-Announces-Name-and-Ticker-Symbol-Changes

Name change to Catheter Precision, Inc. is effective on August 17, 2023, with trading under new ticker symbol VTAK to begin on August 18, 2023

FORT MILL, SC / ACCESSWIRE / August 17, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is today, August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023. The Company's new website will be unveiled shortly in conjunction with the name change. For now, investors can continue to visit www.ramed.com.

David Jenkins, interim CEO of RMED, commented, "The changing of our name signifies the nearing of the completion of our conversion to a company focused solely on cardiac electrophysiology, and away from our previous laser catheter business. We have shut down that previous business and no longer market any of those legacy products."

Jenkins continued, "VTAK is a symbol chosen because of its similarity to V-Tach, a shortened version of Ventricular Tachyarrhythmia, also known as VT. VT, a fast heartbeat of the ventricle, is a disease state which falls under the purview of our VIVO product, where we show, in a 3D computer model of the heart, the earliest electrical activation of the VT. The name VIVO itself is an anachronym for ‘View Into Ventricular Onset'."

RMED new 52 week low

Ok

That price above is wrong!

$RMED - 👆Up 17.8% Pre-Market/ Current Price $0.76
Announces Milestone Achievement for Electrophysiology Division
👉VIVO, the lead product for the electrophysiology division, has been used in more than 1000 ventricular ablation procedures

RMED new 52 week low

RMED new 52/ week low

$RMED's LockeT Device Utilized in Structural Heart Procedures

https://www.accesswire.com/765775/RMEDs-LockeT-Device-Utilized-in-Structural-Heart-Procedures

Provides Evidence of Efficacy in Large Diameter Sheath Procedures, Expanding Use Beyond Electrophysiology Market

FORT MILL, SC / ACCESSWIRE / July 6, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) today announced that its new LockeT device, used as a suture retention device for percutaneous closures, has now been utilized in structural heart procedures. The latest use was in six patients undergoing Watchman & Amulet procedures, where the left atrial appendage is closed off in patients with atrial fibrillation, and two patients receiving the AVEIR Leadless Pacemaker at HCA Trident Medical Center in North Charleston, South Carolina.

HCA Trident Medical Center's Dr. Frank Cuoco, commented, "The LockeT device is another tool in our arsenal that provides ease of use and greatly assists in the femoral closure of the openings from large diameter sheaths. The LockeT allows for greater patient comfort, and hemostasis is achieved in a matter of minutes."

David Jenkins, interim CEO of Ra Medical stated, "Although the electrophysiology market is quite large, we are pleased that the additional evidence of the LockeT use within the structural heart market takes us beyond electrophysiology procedures, and includes not only the LAA device implants, but also the TAVR devices, and certain pacemaker devices such as the AVEIR leadless pacemaker.

Watchman is a product and trademark of Boston Scientific (BSX). AMULET and AVEIR are products and trademark of Abbott (ABT).

RMED new 52 week low

$RMED's Electrophysiology Division Submits Data for CE Mark on LockeT Expects to Receive CE Mark in Third Quarter, 2023

https://www.accesswire.com/764198/RMEDs-Electrophysiology-Division-Submits-Data-for-CE-Mark-on-LockeT-Expects-to-Receive-CE-Mark-in-Third-Quarter-2023

FORT MILL, SC / ACCESSWIRE / June 28, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) today announced that its Catheter Precision subsidiary has submitted to its European Notified Body the data necessary for determination of CE marking on its LockeT product. Recently the company concluded the final step of three-year shelf-life sterility testing which clears the pathway for achievement of the CE Mark.

"This is yet another milestone for us," commented David Jenkins, RMED's interim CEO. "We are excited about the opportunity for LockeT, not only in the US, but also internationally. We expect to receive the CE Mark on LockeT within the third quarter of this year, and with the CE Mark available, it opens the door for European countries and other countries as well. We believe the international market essentially doubles the market size above and beyond just the US market."

About LockeT
Catheter Precision's LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.

$RMED Ra Medical’s Electrophysiology Division Announces First Hospital to Complete 100 Procedures Using the VIVO System


https://www.accesswire.com/760298/Ra-Medicals-Electrophysiology-Division-Announces-First-Hospital-to-Complete-100-Procedures-Using-the-VIVO-System

FORT MILL, SC / ACCESSWIRE / June 12, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has had its first customer, Heart Hospital of New Mexico at Lovelace Medical Center, complete 100 ventricular ablation procedures with the assistance of VIVO, a non-invasive 3D imaging system that identifies the earliest electrical activation of a ventricular arrhythmia.

"This is a significant milestone for Catheter Precision", said David Jenkins, interim CEO. "We continue to believe that physicians and hospitals will find value using VIVO and to see a hospital use it this much in a relatively short period of time demonstrates that the benefits of VIVO are being recognized and that our utilization strategies are working."

VIVO is used to assist physicians in physicians in pre-procedure planning for ventricular ablations. When used in advance of the procedure, VIVO can provide additional information to the physician about the patient's heart to streamline what are often long and complicated procedures lasting 4-5 hours.

Dr Sean Mazer, MD, clinical Electrophysiologist at the Heart Hospital of New Mexico and president of the New Mexico Heart Institute/Lovelace Medical Group says, "We have implemented VIVO in all of our PVC ablations. It has helped speed up and improve the workflow for our most difficult procedures. It has also improved the chances of successful ablation for the patients. Some of these arrhythmias were not treatable without VIVO."

Catheter Precision recently built out a direct sales team in early 2023 to expand upon the successful, but limited launch and to expand its footprint across the United States.

The fundamentals and catalysts are irrelevant. All the information you need is in the price and volume. Look at the daily/weekly. Look at the stocks that have already run and figure out the pattern that caused it. You'll find the chart recipes repeated across various charts in the market, with many that have yet to run.

CHOO CHOO!!

$RMED major R@5.75 train moving the right direction.

Big week for us next week:

I think this rockets to $10 next week.


This will gap up to well above $6.

Get your shares early and fast.

Float is air tight.

Not many shares left to be had.


I am in the same boat: I have shares but I want more shares.

Don't start pumping that here please. Look at what happened a week or so ago. Same action and pulled back to low 4's.

This hit $6.30 today.

Monday it will rocket to $7.30 or more.


Looking for a very strong open on Monday.

Be nice if this could hang above 6

Nice to see shorts getting destroyed here.

Burn these legless, spineless criminals.

Trying to assess this stock. Doing research and see a merger coming up. What other upside factors are at play?

$49. Not joking. May we all use this easy money for good in this brutally vulgar capitalistic society.

yoo call?

$5.81

Moves real quickly Low float. $RMED and $AAPL are two favorites.

broke $5 quickly

THERE RUNNING OUT OF SHARES REAL SOON. ONLY 2 MIL SHARES ISSUED. THIS COULD JUMP REAL HIGH $$$$$$$$$$

UP UP AND AWAY

$RMED waiting for over $6.

HOD was $5.11, we need more like this one! :)

whatta move all day + ah https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170579187&txt2find=rmed